BioSpace News Archive

Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S. commercial release of its recently FDA-approved ALTO ® endograft for the treatment of abdominal aortic aneurysms (AAA). “ALTO represents a differentiation from traditional endovascular aneurysm repair (EVAR) and, with its introduction, a significant la

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be presenting at multiple virtual investor events in August 2020. Shawn Iadonato , Kineta Chief Executive Officer and Craig Philips , President, will present an

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will participate in the William Bla

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively “Noden”) to Stanley Capital (“Stanley Capital”). The total value of the transaction will resul

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2020 following the close of regular trading on Wednesday, August 12, 2020. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company’s website at investors.vareximaging.co

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its second quarter 2020 financial results after the market closes on Thursday, August 13, 2020. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on

CARISMA Therapeutics Inc. , a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two virtual conferences in August 2020 .

EVERSANA™, the leading provider of commercial services to the life science industry, and Havas Health & You (HH&Y), the world’s largest global health and wellness network, today announced an exclusive strategic partnership agreement, inclusive of data, analytics and predictive platforms, combined with commercialization services, to offer to health and wellness clients worldwide.

Today Essity, a leading global hygiene and health company and the maker of TENA incontinence and skin care products announced new findings from a recent consumer survey of incontinence sufferers that uncovered a surprising truth: most women are living with intimate skin irritation, yet are not using the right incontinence products or addressing these issues with their doctor

– Strong global pipeline progress – three U.S. FDA 1 Fast Track Designations; surufatinib U.S. NDA 2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET 3 Exon 14 skipping mutation NSCLC 4 , and surufatinib in pancreatic NET 5 – – Expansion of commercial activities in oncology – Chi-Med to be responsible for medical detailing and marketing for Elunate ® throughout Mainlan